114 related articles for article (PubMed ID: 20482616)
1. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
de Groot M; Teunissen MB; Picavet DI; de Rie MA; Bos JD
Exp Dermatol; 2010 Aug; 19(8):754-6. PubMed ID: 20482616
[TBL] [Abstract][Full Text] [Related]
2. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
3. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
[TBL] [Abstract][Full Text] [Related]
4. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept.
Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H
Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710
[TBL] [Abstract][Full Text] [Related]
5. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
6. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A
Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
8. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
9. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
[TBL] [Abstract][Full Text] [Related]
10. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept].
Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V
Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428
[TBL] [Abstract][Full Text] [Related]
12. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study.
Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S
J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656
[TBL] [Abstract][Full Text] [Related]
13. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
14. Etanercept treatment for children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A;
N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
Lizzul PF; Aphale A; Malaviya R; Sun Y; Masud S; Dombrovskiy V; Gottlieb AB
J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
[TBL] [Abstract][Full Text] [Related]
16. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
17. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
18. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
Tatlican S; Arikok A; Gulbahar O; Eren C; Cevirgen B; Eskioglu F
J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy study on etanercept in patients with plaque psoriasis.
Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
